RU2146943C1 - Method of treatment of patient with mild form of acute pneumonia course - Google Patents

Abstract

FIELD: medicine, pulmonology. SUBSTANCE: method involves carrying out inhalation with human leukocyte interferon (4 doses, twice per a day for 5-8 days) in combination with administration of nonsteroid antiinflammatory agents, expectorants preparations and aloe. Method provides the elimination of antibiotic therapy use. EFFECT: enhanced effectiveness of recovery process, decreased complications and treatment time. 2 ex

Description

 There is a "Method for the treatment of persistent viral diseases" (Patent N 2020957, Bulletin "Invention" N 19, 1994, p. 44, IV Nesterova). The essence of this treatment method is that leukocyte interferon is administered in 0.1 - 0.2 ml 1 time per day in the morning for 2 - 2.5 months and additionally at the same time, antioxidants and retinoids are administered orally in age doses 3 times a day. a day for 2 - 2.5 months, and after 1.5 - 2 months from the start of treatment, stimulants for the production of endogenous plant-derived interferon in oral doses 3 times a day for 2 - 2.5 months are orally administered.

 The disadvantage of this method of treatment is the duration of treatment (2 - 2.5 months), the need to use leukocyte interferon in combination with antioxidants, retinoids and stimulants for the production of endogenous plant-based interferon, as well as intranasal administration of interferon. In acute pneumonia of various etiologies, including viral, it is more advisable to inhale the introduction of leukocyte interferon to directly affect the bronchial tree and lung tissue.

 Also known are methods of inhalation administration of interferon (RU 92014923, RU 1801495).

 We used human leukocyte interferon (CHLI) for inhaled patients with mild acute pneumonia.

 To this group of patients, while taking non-steroidal anti-inflammatory, expectorant drugs and aloe (without antibiotics), 4 doses (1 ampoule) of MFI were inhaled 2 times a day for 5 to 8 days.

 The total number of patients is 10 people. The average age is 34.5 years. Men accounted for 70%, women - 30%.

 The analysis of the treatment results allowed us to establish that the radiological disappearance of infiltration and a complete recovery in all the patients observed.

 The average bed day was 9.7.

 In the control group of patients with mild acute pneumonia who underwent only traditional therapy, including antibiotics, non-steroidal anti-inflammatory, expectorant drugs, aloe and physiotherapy, the average bed-day was 14.2.

 Thus, the proposed method for the use of inhaled administration of CHLI in the treatment of patients with mild acute pneumonia makes it possible to exclude the use of antibiotics and to achieve an earlier recovery.

 The technical result of the proposed method consists in increasing the effectiveness of the recovery process, reducing complications and shortening the treatment time due to the inhalation administration of MFIs and the rejection of antibiotics.

 The results obtained during the study can be illustrated by the following clinical examples.

Example 1
Patient E., 21 years old, medical history N 463, was admitted to the hospital 01/26/96, with complaints of weakness, sweating, headache, cough with sputum, fever.

 Considers himself sick 4 day. Ill acutely. When contacting the clinic on January 22, 1996, FG revealed an infiltration in the lower lobe of the left lung. Sent to a hospital.

Upon examination, the condition is satisfactory, body temperature 37.5 ^o , skin of normal color, respiratory rate - 18 per min, percussion dullness over the lower parts of the lungs on the left, wet rales are heard here.

 In the general analysis of blood ESR - 8 mm / h., Leukocytes - 5.5 g / l., Shift of the leukocyte formula to the left.

In a biochemical blood test, an increase in the content of L ₁ and L ₂ globulins.

 In the analysis of sputum, leukocytes are 30 - 50 in n / a., Flat epithelium - 0 - 2 in n / a.

 The diagnosis was made: acute pneumonia with localization in the lower lobe of the left lung, mild course. Bottom.

 The treatment was prescribed: inhalation of CHLI in 4 doses 2 times a day from 01/29/96 to 02/02/96 (5 days), naproxen inside and scarlet intramuscularly.

 On the 3rd day after the start of interferon therapy, the patient does not complain, auscultatory rales are not heard.

 On FG of lungs from 02.02.96, there are no pathological changes.

 The bed day was 8 days.

Example 2
Patient B., 24 years old, medical history N 1193, was admitted to the hospital March 14, 1995 with complaints of weakness, malaise, and cough with light sputum.

Considers himself ill since 03/07/95, when a cold has developed after a cold, a body temperature has risen to 38 ^o . He was treated on an outpatient basis for acute respiratory infections without effect, on March 9, 1995, his health worsened, a cough appeared with sputum, and fluorographic examination revealed infiltration in the middle lobe of the right lung. Sent to a hospital.

 On examination, the condition is satisfactory, the skin is of a normal color, the respiratory rate is 16 min, dullness of percussion sound to the right below the angle of the scapula and along the axillary lines. Above the projection area of the middle lobe, a large number of moist small-bubble rales are heard.

 In the general analysis of blood ESR - 6 mm / h., Leukocytes - 7.0 g / l., There is no shift in the leukocyte formula.

In a biochemical blood test, an increase in the content of L ₁ and L ₂ globulins.

 Sputum analysis has not been performed - there is little sputum.

 Diagnosed with acute right-sided pneumonia with localization in the middle lobe, mild course. Bottom.

 The treatment was prescribed: inhalation of CHLI in 4 doses 2 times a day from 03/14/95 to 03/22/95 (6 days), methindole inside and scarlet intramuscularly.

 On the 3rd day of treatment, the patient does not show complaints, wheezing is not heard.

 There were no pathological changes in pulmonary FG from 03.22.95.

 The bed day was 9 days.

 Thus, these examples show the effectiveness of inhaled administration of CHLI and the possibility of its use without the use of antibiotics in the treatment of patients with mild acute pneumonia.

Claims (1)

 A method of treating the mild course of acute pneumonia, including the introduction of human leukocyte interferon, characterized in that while taking non-steroidal anti-inflammatory, expectorant drugs and aloe, inhalation of human leukocyte interferon is carried out in 4 doses 2 times a day for 5 to 8 days.